A Phase 3 interventional study of rabeprazole sodium and Placebo in Heartburn, sponsored by Eisai Inc.. Completed at 1 site in United States. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2010-04-06.
Sponsored by Eisai Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 76 studies in Heartburn with a site in United States — 5 open to participants now, 7 under way, 1 of them phase 3. Heartburn · United States.
Among the 76 studies in Heartburn with a site in United States, this one is the 9th largest by enrollment of the 66 interventional ones that give a count, is one of 4 that started in 2005, is one of 18 in phase 3, and was the 5th registered.
154 studies on the registry are indexed under Heartburn; 12 are open to participants now.
Browse Heartburn studies →5 of the 76 studies in Heartburn with a site in United States are open now. Recruiting first, the newest first:
Arizona State University · Sites in United States
Ages 18+
Peach Perfect · Sites in United States
Ages 18–60
Phathom Pharmaceuticals, Inc. · Sites in United States
Ages 15–50 · Women only
Mayo Clinic · Sites in United States
Ages 18+
McMaster University · Sites in United States, Canada
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 8 Heartburn studies recruiting now, 5 set no upper age limit and 3 stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
76 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 13 · Phase 3 20 · Phase 4 8
First in 1999; this study’s year is marked. 4 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 629 is above the median of 100 across 127 interventional studies indexed under Heartburn.
Median enrollment 98 across the 66 interventional studies, 414 across the 10 observational. Of the 63 that completed or were terminated, 28 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 76 have an industry lead sponsor. The 10 most frequent:
This study is registered under Eisai Inc., one of the names counted as Eisai Co., Ltd.. Under that name alone:
Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.
Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.
Eisai Co., Ltd. has 3 studies filed under Heartburn — fewer than ten, so there is no comparison to draw.
3 of the studies in Heartburn with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01696734Phase 3M.D. Anderson Cancer CenterDomperidone in Treating Patients With Gastrointestinal Disorders | 2027-10-31 |
| NCT05976165Mayo ClinicA Study of Breath Testing for Small Intestinal Bacterial Overgrowth | 2027-01-01 |
| NCT07927296Arizona State UniversityVinegar and Heartburn | 2027-05-15 |
Add all 3 to your calendar (.ics) → With an account.
Among the 76 studies in Heartburn with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the safety and efficacy of rabeprazole sodium 10 mg in treating frequent heartburn.
This is a multicenter, double-blind, randomized, placebo-controlled study to investigate the safety and efficacy of rabeprazole 10 mg in treating frequent heartburn. The study will last for up to five weeks and consists of the following three phases: a one to two week screening period that includes a one-week, single-blind, placebo run-in phase, a two week double-blind, randomized treatment phase, and a one week single-blind, placebo follow-up phase.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral placebo tablet
Other: Placebo
oral rabeprazole 10 mg enteric-coated tablet
Drug: rabeprazole sodium
Following a one week single-blind, placebo run-in phase, patients will receive rabeprazole 10 mg orally, once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.
Also known as: Aciphex
Following a one week single-blind, placebo run-in phase, patients will receive placebo orally, once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.
Complete Heartburn Relief During the First Full 24-Hour Period in the ITT Population.
Subject was considered "complete relief" if he/she did not heartburn during the nighttime of the first dose date and no heartburn during the daytime of 1 day after the first dose date. The difference in complete relief within the first 24 hours between treatment groups was tested using a continuity corrected chi-square test without adjustment baseline heartburn severity.
Time frame: first 24 hours
Summary of Percentage of Heartburn-free Daytimes, Intent-to-Treat (ITT) Population
comparison between placebo and treatment will be analyzed using two-sample t-test.
Time frame: 14-day treatment period.
Summary of Percentage of Heartburn-Free Nighttimes,Intent-to-Treat (ITT) Population
comparison between placebo and treatment will be analyzed using two-sample t-test.
Time frame: 14-day treatment period.
Change From Baseline in Average Regurgitation Severity Score Between Placebo and Rabeprazole.
comparison between placebo and treatment will be analyzed using two-sample t-test.
Time frame: 14-day treatment period.
Change From Baseline in Average Belching Severity Score Between Placebo and Rabeprazole.
comparison between placebo and treatment will be analyzed using two-sample t-test.
Time frame: 14-day treatment period.
This study was recruited at 39 centers in the US during the period of 10-Oct-2005 and 16-Mar-2006.
| Milestone | Placebo | Rabeprazole 10 mg |
|---|---|---|
| Started | 310 | 319 |
| Completed | 292 | 308 |
| Not completed | 18 | 11 |
| Withdrew: Adverse event | 5 | 2 |
| Withdrew: Lack of efficacy | 0 | 1 |
| Withdrew: Lost to follow-up | 3 | 4 |
| Withdrew: Physician decision | 1 | 1 |
| Withdrew: Withdrawal by subject | 3 | 0 |
| Withdrew: Protocol violation | 3 | 0 |
| Withdrew: Non-compliance with study drug | 2 | 1 |
| Withdrew: Other | 1 | 2 |
comparison between placebo and treatment will be analyzed using two-sample t-test.
Results for this outcome have not been posted.
comparison between placebo and treatment will be analyzed using two-sample t-test.
Results for this outcome have not been posted.
comparison between placebo and treatment will be analyzed using two-sample t-test.
Results for this outcome have not been posted.
comparison between placebo and treatment will be analyzed using two-sample t-test.
Results for this outcome have not been posted.
Subject was considered "complete relief" if he/she did not heartburn during the nighttime of the first dose date and no heartburn during the daytime of 1 day after the first dose date. The difference in complete relief within the first 24 hours between treatment groups was tested using a continuity corrected chi-square test without adjustment baseline heartburn severity.
| participants | Placebo | Rabeprazole 10 mg |
|---|---|---|
| Complete Heartburn Relief During the First Full 24-Hour Period in the ITT Population. | 114 | 163 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 2/310 (0.6%) | 4/310 (1.3%) |
| Rabeprazole 10 mg | — | 1/319 (0.3%) | 7/319 (2.2%) |
| Event | Placebo | Rabeprazole 10 mg |
|---|---|---|
| Appendicitis perforatedGastrointestinal disorders | 1/310 | 0/319 |
| abortion spontaneousPregnancy, puerperium and perinatal conditions | 1/310 | 0/319 |
| Chest painCardiac disorders | 0/310 | 1/319 |
| Event | Placebo | Rabeprazole 10 mg |
|---|---|---|
| NasopharyngitisInfections and infestations | 4/310 | 7/319 |
| Age, Categorical(Participants) | Placebo | Rabeprazole 10 mg | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 285 | 298 | 583 |
| >=65 years | 25 | 21 | 46 |
| Age Continuous(years) | Placebo | Rabeprazole 10 mg | Total |
|---|---|---|---|
| Mean | 45.4 ± 13.3 | 44.1 ± 14.4 | 44.7 ± 13.8 |
| Sex: Female, Male(Participants) | Placebo | Rabeprazole 10 mg | Total |
|---|---|---|---|
| Female | 198 | 186 | 384 |
| Male | 112 | 133 | 245 |
| Race (NIH/OMB)(Participants) | Placebo | Rabeprazole 10 mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 2 | 2 | 4 |
| Asian | 4 | 5 | 9 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 25 | 31 | 56 |
| White | 236 | 248 | 484 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 43 | 33 | 76 |
| Region of Enrollment(participants) | Placebo | Rabeprazole 10 mg | Total |
|---|---|---|---|
| United States | 310 | 319 | 629 |
The record gives a start of Oct 2005, a primary completion of Mar 2006 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2009, 3 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rabeprazole